Moderna's Cancer Vaccine Data Are Real — the Argument Is Over What They're Worth
Published on 10/29/2026 at 06:40 | Editorial boerse-global.de
Moderna's shares have been on a tear, and Wall Street's reaction to the company's melanoma vaccine results now splits neatly into two camps. One raised its price target. The other stepped to the sidelines. Neither disputes the science.
That distinction matters more than any single analyst call. A clinical win and a fairly priced stock are two separate claims, and conflating them risks counting the same medical progress twice — first as a trial success, then again as fresh confirmation from the market.
What the trial actually showed
The combination of intismeran and pembrolizumab, developed with Merck, cut the risk of melanoma recurrence or death by 42% compared with pembrolizumab alone in the Phase 3 INTerpath-001 study, according to company figures. The risk of distant metastasis or death fell by 38%. At 24 months, relapse-free survival stood at 82.2% on the combination versus 70.0% in the comparator arm.
The trial enrolled patients whose melanoma had been fully removed, per Merck. Detailed results were presented Saturday at ESMO and accepted for publication in the New England Journal of Medicine — a scientific endorsement that adds weight but says nothing about the share price.
Moderna and Merck said last week they are preparing US regulatory filings, with a market launch expected in 2027, Reuters reported. That timeline gives investors an economic anchor. It is still a projection, not an approval.
Should investors sell immediately? Or is it worth buying Moderna?
Two houses, two yardsticks
Piper Sandler lifted its price target to $230 from $167 on Monday while keeping an Overweight rating, pointing to the INTerpath-001 data. Media reports linked the move to the stock's rebound — a gain of 2.6% that day.
William Blair went the other way on Tuesday, downgrading Moderna to Market Perform from Outperform. The reason was valuation after the sharp rally, not any clinical disappointment. Analyst Myles Minter called the melanoma results support for a potential new standard of care, while flagging uncertainty in other tumor types.
Read together, the two actions describe a disagreement about price rather than about efficacy. One side assigns more value to the clinical advance; the other argues the share price already reflects much of it. For investors, that tension is more useful than hunting for a single definitive analyst signal.
The leap beyond melanoma
Here lies the real limit on the enthusiasm. A strong result in melanoma does not automatically carry over to other cancers. The positive reading can rest on the demonstrated effect; broader applications should remain a possibility, not a settled success.
The stock gained 3.1% today, moving in the opposite direction of William Blair's more cautious stance — though no explanation for the advance follows from that alone.
The rebound itself looks less like a fresh breakthrough than a repricing of known data: investors giving published results and a higher target their due. That can be a rational move. It does not, by itself, make the risk-reward equation more attractive.
Moderna now holds a substantial clinical argument. Whether it grows into a commensurately large commercial success is the next question. The rally credits the progress — it does not answer that question.
Ad
Moderna Stock: New Analysis - 29 October
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
